Regular ArticleThe Relationship between Telomere Length and Telomerase Activity in Gynecologic Cancers
References (28)
- et al.
Telomere shortening in chronic liver diseases
Biochem Biophys Res Commun
(1995) - et al.
Telomere shortening in uterine leiomyomas
Am J Obstet Gynecol
(1998) The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats
Cell
(1989)- et al.
Alteration in length of telomeric repeats in lung cancer
Lung Cancer
(1994) - et al.
A survey of telomerase activity in human cancer
Eur J Cancer
(1997) - et al.
Telomerase activity in normal leukocytes and in hematologic malignancies
Blood
(1995) - et al.
Inhibition of telomerase activity by cisplatin in human testicular cancer cells
Eur J Cancer
(1997) - et al.
Human telomeres contain at least three types of G-rice repeat distributed non-randomly
Nucleic Acids Res
(1989) - et al.
Telomere reduction in human colorectal carcinoma and with aging
Nature
(1990) - et al.
Telomere reduction in hematologic cells
Int J Hematol
(1993)
Telomerase, cell immortality, and cancer
Cold Spring Harb Symp Quant Biol
Structure and function of telomeres
Annu Rev Genet
Changes of telomere lengths in human intracranial tumours
Hum Genet
Cited by (23)
Telomere fusion threshold identifies a poor prognostic subset of breast cancer patients
2015, Molecular OncologyCitation Excerpt :Our data show that telomere shortening can be extensive in breast tumours, yet this appears to occur in the presence of telomerase, which is detected in the majority of breast tumours analysed (Hiyama et al., 1996; Pearson et al., 1998). However an absence of any relationship between the levels of telomerase activity and telomere length has been reported in Breast cancer (Lu et al., 2011) and other tumour types (Wang et al., 2002). We have recently shown that short telomeres can be detected in early stage lesions for example in colorectal adenomatous polyps (Roger et al., 2013) and in chronic lymphocytic leukaemia prior to clinical progression (Lin et al., 2010, 2014).
Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women
2011, Annals of OncologyCitation Excerpt :Thus, cyclic withdrawal of progestin, rather than continuous therapy, has been proposed as an alternative strategy for patient treatment [31]. The receptors themselves are not the sole participants in this process, however, as the response to treatment with progestin may be further modified by tumor-specific perturbations of the downstream cellular apoptotic signaling pathways [31]. Uterus-sparing hormonal treatment of AEH and well-differentiated carcinoma with a combination of injected GnRH analogue and progestin-impregnated IUD can be effective in some patients.
Distinct modulation of telomere length in two T-lymphoblastic leukemia cell lines by cytotoxic nucleoside phosphonates PMEG and PMEDAP
2010, European Journal of PharmacologySpeculation and Deductive Reasoning About Ovarian Epithelial Carcinogenesis and New Horizons
2003, Diagnosis and Management of Ovarian Disorders, Second Edition
- 1
To whom correspondence and reprint requests should be addressed at Department of Obstetrics and Gynecology, Dokkyo University School of Medicine, 880 Kitakobayashi, Mibu-machi, Shimotsuga-gun, Tochigi 321-0293, Japan. Fax: 00-81-282-86-6856. E-mail: [email protected].